What decision does “Disease-Model Selection as a Scientific Decision” help make?

It supports a bounded decision about which model is fit for the mechanism and decision being tested. The framework keeps alternatives, evidence, counterevidence, uncertainty, and the fastest falsification test visible.

Can computation validate the final scientific claim?

No. No model fully represents human disease, and model choice can determine the apparent answer. Computation can prioritize and eliminate directions; final validation remains with the appropriate domain methods and accountable specialists.

When should the project stop or reframe?

Stop or reframe when the target-disease link is not robust, the mechanism lacks a discriminating prediction, tractability depends on unsupported assumptions, public data contradict the thesis, or the next credible validation belongs in a qualified experimental program.

Drug Discovery

Disease-Model Selection as a Scientific Decision

Published 2026-08-22 · Updated 2026-08-22

Answer in brief

Disease-Model Selection as a Scientific Decision can shorten the search only by eliminating weak directions early. Start with which model is fit for the mechanism and decision being tested; compare mechanisms against construct validity, predictive validity, species or system differences, endpoints, heterogeneity, and feasibility; and try to break the ranking with this challenge: identify a known clinical or human-biology feature the model should reproduce. A negative result is valuable when it prevents the wrong validation cycle.

Evidence status: Decision-method guide; not a completed investigation or final validation.

The decision this guide supports

which model is fit for the mechanism and decision being tested

Why the problem is difficult

The article-specific identification challenge is whether the question “which model is fit for the mechanism and decision being tested” can be resolved using construct validity, predictive validity, species or system differences, endpoints, heterogeneity, and feasibility, rather than merely restated in new language.

A falsifier-first workflow

Define the decision precisely: which model is fit for the mechanism and decision being tested.
Build a source and data ledger around construct validity, predictive validity, species or system differences, endpoints, heterogeneity, and feasibility.
Compare the inherited route with a mechanistically distinct alternative and a constraint-based null.
Actively search for the strongest counterevidence relevant to this decision, including boundary cases and prior failures.
Run the lowest-cost discriminating challenge: identify a known clinical or human-biology feature the model should reproduce.
Record pursue, reframe, or stop, the confidence level, the evidence ceiling, and who owns downstream validation.

Decision criteria

Decision impact: would the result materially change the choice about which model is fit for the mechanism and decision being tested?
Evidence fit: does the available evidence—construct validity, predictive validity, species or system differences, endpoints, heterogeneity, and feasibility—directly address the decision rather than merely correlate with it?
Discrimination: does the preferred route predict an outcome a credible alternative does not?
Robustness: does the ranking survive the challenge “identify a known clinical or human-biology feature the model should reproduce”?
Validation boundary: is the conclusion no stronger than the available sources, data and computation?

Supporting evidence

construct validity, predictive validity, species or system differences, endpoints, heterogeneity, and feasibility

Counterevidence

For this decision, a result from “identify a known clinical or human-biology feature the model should reproduce” that reverses or flattens the ranking must remain visible even when it is commercially inconvenient.

Computation

Here computation earns its place only if it changes the choice about which model is fit for the mechanism and decision being tested or exposes why the available evidence cannot resolve it.

Fastest falsifier

identify a known clinical or human-biology feature the model should reproduce

When to stop or reframe

A decision-specific stop trigger is failure of the challenge “identify a known clinical or human-biology feature the model should reproduce” without an independently supported alternative mechanism.

Evidence ceiling

No model fully represents human disease, and model choice can determine the apparent answer.

Sources and starting points

Open Targets Platform — Integrated public evidence connecting therapeutic targets and diseases.
ChEMBL — Curated bioactivity information for compounds, assays, and targets.
ClinicalTrials.gov — Official registry and results database for clinical studies; registry records are not proof of efficacy.
PubMed — Primary biomedical literature discovery; individual studies require direct appraisal.
FDA Drug Development and Approval Process — Additional authoritative starting point selected for this decision area; applicability must be checked against the precise question.
UniProt — Additional authoritative starting point selected for this decision area; applicability must be checked against the precise question.

Continue the decision journey

Explore the full topic hub · Editorial standard · Scientific Oracle consulting

Frequently asked questions

What decision does “Disease-Model Selection as a Scientific Decision” help make?: It supports a bounded decision about which model is fit for the mechanism and decision being tested. The framework keeps alternatives, evidence, counterevidence, uncertainty, and the fastest falsification test visible.
What is the fastest useful test?: identify a known clinical or human-biology feature the model should reproduce
Can computation validate the final scientific claim?: No. No model fully represents human disease, and model choice can determine the apparent answer. Computation can prioritize and eliminate directions; final validation remains with the appropriate domain methods and accountable specialists.
When should the project stop or reframe?: Stop or reframe when the target-disease link is not robust, the mechanism lacks a discriminating prediction, tractability depends on unsupported assumptions, public data contradict the thesis, or the next credible validation belongs in a qualified experimental program.